Of the 20% of invasive HER2 type breast cancers that are treated with HER2 targeted therapeutics, such as trastuzumab (Herceptin), the monoclonal antibody targeting HER2, ∼25% of patients eventually develop resistance. The gene discussed is ERBB2; the disease is breast carcinoma.